- Home
- MGN vs LTRN Comparison
MGN vs LTRN Comparison
Compare MGN & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | LTRN |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 31.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MGN | LTRN |
|---|---|---|
| Price | $2.67 | $2.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 488.0K | 45.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $2.45 |
| 52 Week High | $3.99 | $5.74 |
Technical Indicators
Market Signals| Indicator | MGN | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 44.04 |
| Support Level | $1.42 | $2.49 |
| Resistance Level | N/A | $3.65 |
| Average True Range (ATR) | 0.44 | 0.21 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 77.52 | 40.63 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.